Showing posts with label hcfo. Show all posts
Showing posts with label hcfo. Show all posts

Monday, July 13, 2020

152 CMAAO CORONA FACTS and MYTH BUSTER Covid in Children, Neurology


152 CMAAO CORONA FACTS and MYTH BUSTER Covid in Children, Neurology

Dr K Aggarwal
President CMAAO
With inputs from Dr Monica Vasudev
9743: Minutes of Virtual Meeting of CMAAO NMAs on “Covid in children & Covid and neurology”

11th July, 2020, Saturday, 9.30am-10.30am

Participants, Member NMAs

Dr KK Aggarwal, President CMAAO
Dr Yeh Woei Chong, Singapore Chair CMAAO
Prof Ashraf Nizami, Pakistan First Vice President CMAAO
Dr N Gnanabaskaran, President Malaysian Medical Association
Dr Marthanda Pillai, Member World Medical Council
Dr Alvin Yee-Shing Chan, Hong Kong, Treasurer CMAAO
Dr Koh Kar Chai, Malaysia Co Chair CMAAO
Dr Marie Uzawa Urabe, Japan Medical Association
Dr Qaisar Sajjad, Pakistan Medical Association, Secretary
Dr Prakash Budhathoky, Nepal Medical Association

Invitees

Dr Russell D’Souza, UNESCO Chair in Bioethics, Australia
Dr Sanchita Sharma, Editor IJCP Group


Prof Ashraf Nizami and Dr Alvin Yee-Shing Chan spoke on Covid in children and Covid and neurology, respectively. Here are key points from each presentation.

Covid-19 in children and Pakistan

Prof Ashraf Nizami
First Vice President CMAAO
Immediate Past President PMA Center
President PMA Lahore

In his presentation, Prof Ashraf Nizami spoke on Covid-19 in children and also highlighted the role of government and particularly the Pakistan Medical Association (PMA) in dealing with Covid-19 in Pakistan. The first case was reported in Pakistan on 6th February.

  • There was a general perception that children are not affected by this pandemic. But the fact is that all children of all ages in all countries are affected. This is a universal crisis and will have lifelong impact for some children as it is not just a health issue. It is also social and psychological issue.

  • Clinical symptoms in children include abdominal pain, diarrhea and vomiting, red rash, cracked lips, red eyes, high fever, swollen glands on neck and swollen hands and feet.

  • As per data on July 1, about 7.28% of the total reported cases in Pakistan are in people below 19 years of age. The mortality is 0.46% (16 out of 3501 under 15 years). Three suspected cases of Kawasaki disease have been reported in Lahore; also from Karachi, Rawalpindi and Islamabad.

  • Covid has an impact on social growth. About 30% of industry is affected. Education is disturbed and only about 30% of children in Pakistan have access to technology in education (online). Healthcare services have been affected. Covid has also affected the physical and mental growth of children.

  • The pandemic has led to anxiety and depression not only in children but also the parents. Incidence of domestic violence against women has increased due to lockdown, which has an impact on children and the family. Exploitation and child abuse have happened.

  • Covid-19 has compromised access to health services due to lockdown; the basic health services are delayed due to SOPs in place. Polio vaccination has been affected; besides Pakistan and Afghanistan, recent outbreaks have been reported in Africa, East Asia and the Pacific.

  • The government is creating awareness about the disease; special institution have been designated for children. Special counters have been created in hospitals.

  • According to UNICEF, adequate water, sanitation and hygiene services for households, schools and healthcare facilities are essential to prevent spread of infectious diseases including Covid-19; 3 billion homes do not have soap and water; 900 million children do not have soap and water at schools.

  • PMA is an active participant in Covid-19 activities. It was the first organization in Pakistan which spoke about Covid-19 and created awareness and raised an alarm about the outbreak. It also looks after coordination among doctors, government, social activities and people. A scientific meeting was organized for family physicians, who are considered as front liners. PMA is also developing guidelines with information derived from WHO, CMAAO, London School of Economics etc.

  • PMA is working on telemedicine facilities, analysis of government policies, plans and actions. It is playing an active role in advocacy and implementation of WHO recommendations as per local needs as well as international experiences.

  • PMA is pressing upon the government that curative services should not be compromised, to start immunization services with all SOPs; it is critical of the government’s decision to reopen schools. Psychology and psychiatric teleconsultations are being planned.


Covid and Neurology

Dr Alvin Yee-Shing Chan
Treasurer CMAAO
Vice Chairman, HKMA Charitable Foundation

  • About 36.4 % of Covid patients from Wuhan China had neurological involvement; manifestations were more in cases of severe infection.

  • Acute cerebrovascular diseases occurred in 5.7% of those severe cases vs 0.08% of milder cases.

  • 14% of severe cases had impaired consciousness vs 2.4% of mild cases.

  • Musculoskeletal injury occurred in 19.3% of severe cases vs 4.8% of mild cases.

  • Neurological signs and symptoms are much higher in patients in intensive care: mental confusion and agitation (69%), diffuse corticospinal tract signs with enhanced tendon reflexes, ankle clonus, bilateral extensor plantar reflexes (67%).

  • 33% of discharged patients (33%) had dysexecutive syndrome consisting of inattention, disorientation, or poorly organized movements in response to command

  • MRI brain, in most of the patients, will show leptomeningeal enhancement, bilateral frontotemporal hypoperfusion, ischemic stroke; encephalopathic pattern on EEG.

  • Clinically, these patients may have milder symptoms (hyperosmia, anosmia, headache, weakness, altered consciousness); patients with more severe infection have encephalitis with demyelination, neuropathy, and stroke.

  • Invasion of the medullary cardiorespiratory center by the SARS CoV-2 virus may cause refractory respiratory failure in ICU patients.

  • The route of entry is mostly through olfactory bulbs – olfactory tracts in the brain.

  • Human coronaviruses have neuroinvasive capability. Misdirected host immune responses can damage the CNS, which is associated with autoimmunity in the susceptible persons, resulting in virus induced neuro-immunopathology. The virus replication directly damages the CNS.  ACE2 receptors occur in olfactory epithelium 70 times more than in tracheal or nasal epithelium. This is why anosmia occurs so frequently in this disease.

  • The ACE2 receptor expression differs in neurons and glial cells and so immunopathology differs in different persons.

  • Since ACE2 receptors are present in brain cells, the BBB presents no problem to the new corona virus. The virus has been detected in brain samples on autopsies and offers an explanation about the neurological sequelae even when the patients survive.

  • Possible mechanism of direct neuronal damage: The trans-neuronal retrograde machinery is a possible route of neuronal invasion. The virus first infects peripheral neurons to invade the CNS via the axonal retrograde transport. It infects another neuron via synapses. The virus is released by exocytosis in the presynaptic terminal. It then binds to ACE2 receptor on the postsynaptic neuron. It gains entry into the neuroplasm via the receptor-mediated endocytosis. It causes cell death via apoptosis.

  • Covid-19 induces anti-cardiolipin antibodies → endothelialitis → thrombosis (venous and arterial) → stroke, cerebrovascular accidents.

  • The direct attack on neurons will cause milder cases, but if there is massive invasion of key neuronal cells, this may cause dysexecutive function. The vasculitis and endothelitis is instrumental in severe cases → stroke, and cell death due to ischemia.

  • Hong Kong has very few pediatric patients and they have mild infection. There is resurgence in community spread with more than 40 cases with no obvious source. 7500 tests in a day, which is inadequate. No medical health staff has been infected through hospital or clinic. The silent cases in community are a cause of concern.

Acute presentation

Dr KK Aggarwal
President CMAAO

Look for the following points in every patient who presents with onset of illness less than
3 months. Classifying patients accordingly makes it easier to manage them.

  • Is the clinical presentation of Covid is due to inflammation? There will be signs of inflammation like IL-6, ESR, CRP, ferritin → Give anti-inflammatory drugs; steroids are the most potent anti-inflammatory drugs
  • Can this be because of hypercoagulable state? e.g. thrombotic stroke/MI/appendicitis/gangrene/happy hypoxia (microclot formation in lung vessels): Do d-dimer; high d-dimers mean hypercoagulable state  
  • Is there any immunological reaction (immediate or delayed) - humoral? Vasculitis, look for rash, CRP is normal, high platelets;
  • Is there cellular immunological response? Cytokine crisis
  • Except for hypercoagulable state, all will respond to steroids. So, combination of LMWH and steroids is standard treatment.
  • Some patients may have simple viral response and illness will resolve spontaneously in 2-3 days; some will show a bacterial response with slightly high polymorphs – typhoid test may be falsely positive in such patients; some patients may have low CD4 count indicating HIV-like activity.



























































































 


Wednesday, May 20, 2020

CMAAO CORONA FACTS and MYTH BUSTER 99 Pregnancy


CMAAO CORONA FACTS and MYTH BUSTER 99 Pregnancy

Dr K K Aggarwal
President Confederation of Medical Associations of Asia and Oceania, HCFI, Past National President IMA, Chief Editor Medtalks

888: Pregnancy and COVIUD 19Source UPTODATE

1.     Pregnant women should follow the same recommendations as nonpregnant persons for avoiding exposure to the VOVID virus.

2.     Pregnant health workers in the third trimester, particularly those ≥36 weeks, stop face-to-face contact with patients.

3.     Clinical manifestations of COVID-19 in pregnant women are similar to those in nonpregnant individuals.

4.     A positive test for SARS-CoV-2 generally confirms the diagnosis of COVID-19, although false-positive and false-negative tests are possible.

5.     Pregnancy does not appear to increase susceptibility to infection or worsen the clinical course, and most infected mothers recover.  However, severe disease necessitating maternal intensive care unit admission and need for extracorporeal membrane oxygenation can occur.

6.     Infected women, especially those who develop pneumonia, appear to have an increased frequency of preterm birth and cesarean delivery. These complications are likely related to severe maternal illness as intrauterine infection does not appear to occur, but this is still under investigation. A few possible early newborn infections and one possible placental infection have been reported.

7.     The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) have issued guidance regarding prenatal care during the COVID-19 pandemic

8.     For the general population, the Centers for Disease Control and Prevention recommend avoiding glucocorticoids in COVID-19-positive persons because of the potential for adverse effects on the course of the disease. Because of the clear benefits of antenatal betamethasone administration between 24+0 and 33+6 weeks of gestation in patients at risk of preterm birth within seven days, ACOG continues to recommend its use for standard indications to pregnant patients with suspected or confirmed COVID-19.

9.     For most women with preterm COVID-19 and nonsevere illness who have no medical/obstetric indications for prompt delivery, delivery is not indicated and ideally will occur sometime after a negative testing result is obtained or isolation status is lifted, thereby minimizing the risk of postnatal transmission to the neonate. Severely ill patients at least 32 to 34 weeks of gestation with COVID-19 pneumonia may benefit from early delivery.

10. In areas where the infection is active, we believe testing all patients upon presentation to labor and delivery (or the day before if a scheduled admission) is reasonable, if testing is available. In a city with a high infection prevalence, a high proportion of asymptomatic patients (13.5 percent in one study) admitted for delivery tested positive, which has clinical implications for triage, staff, and newborn care.

11. Generally, management of labor is not altered in women giving birth during the COVID-19 pandemic or in women with confirmed or suspected COVID-19. SARS-CoV-2 has not been detected in vaginal secretions or amniotic fluid, so rupture of fetal membranes and internal fetal heart rate monitoring may be performed for usual indications, but data are limited. COVID-19 is not an indication to alter the route of delivery. The partner/support person should be screened in accordance with hospital policies and those with any symptoms consistent with COVID-19, exposure to a confirmed case within 14 days, or a positive test for COVID-19 within 14 days should not be allowed to attend the labor and birth.

12. In patients with known or suspected COVID-19, neuraxial anesthetic is not contraindicated and has several advantages in laboring patients. The Society of Obstetric Anesthesia and Perinatology suggests suspending use of nitrous oxide for labor analgesia in these patients because of insufficient data about potential aerosolization of nitrous oxide systems.

13. At delivery of patients with known or suspected COVID-19, some institutions have chosen to prohibit delayed cord clamping in term infants, in whom the benefits are modest, to minimize newborn exposure to any virus in the immediate environment and reduce the chances that the newborn will require phototherapy for jaundice.

14. NSAIDs are commonly used for treatment of postpartum pain; however, there are anecdotal reports of possible negative effects of NSAIDs in patients with COVID-19. Given the uncertainty, use paracetamol (acetoaminophen). If NSAIDs are needed, the lowest effective dose should be used.

15. Infants born to mothers with known COVID-19 are COVID-19 suspects and should be tested, isolated from other healthy infants, and cared for according to infection control precautions for patients with confirmed or suspected COVID-19.

16. Whether to separate a mother with known or suspected COVID-19 and her infant is determined on a case-by-case basis. If the infant tests positive, separation is unnecessary. If separation is indicated (mother is on transmission-based precautions) but not implemented, other measures may be utilized to reduce potential mother-to-infant transmission, including physical barriers and ≥6 feet separation, personal protective equipment and hand hygiene, and utilization of other healthy adults for infant care (feeding, diapering, bathing).

17. The virus has only been found in one sample of breast milk, but data are limited.

18. Droplet transmission to the new-born could occur through close contact during feeding.

19. In mothers with confirmed COVID-19 or symptomatic mothers with suspected COVID-19, to minimize direct contact, ideally, the infant is fed expressed breast milk by another caregiver until the mother has recovered or been proven uninfected, provided that the other caregiver is healthy and follows hygiene precautions. In such cases, the mother should wear a mask and thoroughly clean her hands and breasts before pumping; the pump parts, bottles, and artificial nipples should be cleaned as well. If she breastfeeds the infant directly, similar personal hygienic precautions should be taken.


20.   Remdesivir is the most promising and has been used without reported fetal toxicity in some severely ill pregnant women.